Research notes
Stay informed with the most recent market and company research insights.

Research Notes
The big dance beckons
Neurizon Therapeutics
July 17, 2026
NUZ has completed enrolment in Regimen I of the HEALEY ALS Platform Trial for NUZ-001, with all 250 participants enrolled (recently increased from 160 patients). Topline efficacy and safety results have been brought forward again, now expected in late Q2 CY27 versus the prior 3Q CY27 guidance from our May note. No change to our SPECULATIVE BUY rating or A$0.20 target. This is a timeline update, not a valuation trigger.
Model update
Commonwealth Bank
July 16, 2026
We make updates to our forecasts ahead of the FY26 result in August. Net result is 1-2% downgrades to FY27-28F EPS. 12 month target price reduces 1% to $117.63. Sell retained, given stretched valuation metrics remain implied in the share price (c.26x PER, 3.7x PBV, 2.9% cash yield).
Delivers in-line Q4 with coal beat
BHP Group
July 16, 2026
A good end to FY26 for BHP, with an operational result largely in line with consensus and a touch ahead of our estimates in places. Normally a source of volatility, BHP’s coal operations posted decent consensus beats at both BMA and NSWEC. FY27 guidance looks steady versus our existing estimates, although consensus does look high on group copper. Best-in-breed global diversified miner in what remains a healthy upcycle for resources. We maintain our HOLD rating and A$60.20 target price.
Big step into the UK
Intelligent Monitoring Group
July 16, 2026
IMB has agreed to acquire ADT UK Residential from JCI for £180m (A$345m), funded by £155m debt and £25m scrip, at an attractive valuation of ~4x FY26 EBITDA. ADT UK brings a highly recurring (93%) UK residential base, lifting pro forma EBITDA to ~A$130m. Including the deal from 2H27, we forecast FY28 EBITDA +124%, NPATA +46% and EPSA +23%, with pro forma leverage of ~3x. The investment case will now hinge on the performance of the UK business, given its scale relative to ANZ. We lift our target price to A$1.20 (from A$1.00).
4Q26: Progress outpacing the price
Microba Life Sciences
July 16, 2026
MAP's 4Q26 result delivered the strongest evidence yet that the enterprise account strategy is working, with a materially larger disclosed pipeline and a specific CY2027 break-even target. Core testing revenue hit a new record and operating burn fell 38% YoY. Core volume of 22,418 tests came in modestly short of the 24,000+ guided range, though an exit run-rate above 25,000 points to timing rather than demand. The reset cost base, strong underlying growth and new market expansion opportunities set up a quick path back into investors' good graces. We retain Speculative Buy, target price unchanged at A$0.12 p/s.
Solid Q4 drives net debt right down
Amplitude Energy
July 15, 2026
A solid Q4 production and sales result, with Orbost's continued outperformance the obvious standout. As we expected, revenue dipped on softer Victorian and South Australian spot prices through the quarter, though by less than we had allowed for. FY26 closed with records across the board. Group production of 27.6PJe (+3%), revenue of A$285.8m (+7%) and a record realised gas price of A$10.35/GJ (+4%), while net debt was slashed 85% yoy to A$37.2m. Management's outlook commentary was very positive, with the flagship Orbost plant setting fresh production records post quarter end. AEL is our top energy sector pick following recent share price weakness. We maintain our BUY rating and A$3.05 target price.
Much ado about Simandou
Rio Tinto
July 15, 2026
RIO posted a healthy Q2 where it matters, with Pilbara shipments beating consensus (+2%), while we see the headline Simandou miss (-68% vs consensus) as a net positive: a slower Simandou ramp supports iron ore benchmarks, and each US$10/t on the benchmark is worth ~US$2.5bn of annual EBITDA to RIO's far larger Pilbara business. The sting in the tail was Kennecott, with a late June converting furnace breach requiring a ~75-day full rebuild, hitting H2 refined copper and gold output (total copper including saleable matte unchanged). Copper C1 guidance halved to US30-50c/lb, on strong by-prod prices, a material margin tailwind into the H2 result. Trading back close to where we see fair value, RIO remains one of the highest quality global exposures to a sector enjoying a multi-year upcycle (albeit not without its volatility). We maintain our HOLD rating, A$163.00 TP (was A$165.00).
2Q26 result: revenue and cash beat supports liquidity
29 Metals
July 15, 2026
Copper production missed forecasts, but copper sales and zinc, gold and silver production made up for it, leading to a ~30% revenue beat versus forecasts. Liquidity remains sound. Cash and liquidity came in ahead of expectations. Maintain HOLD rating with a A$0.26ps target price (previously A$0.27ps).
4Q26 result: in line, additional capex flagged for FY27
Evolution Mining
July 15, 2026
4Q26 result and FY26 guidance were largely in line with expectations. FY27 outlook commentary flagged higher capex than previously expected and inflationary impacts to AISC, which affect FY27 cash flow forecasts. Maintain BUY with a A$14.60ps target price (previously A$16.00ps).
Facing headwinds
Worley
July 15, 2026
The late June trading update lifted the FY26 Middle East impost to $60m EBITA (from $30-40m) and quantified the 2H FX impact as $50m. Medium term, WOR should see some earnings support from Middle East repair activity and a broader uplift in global upstream hydrocarbon spending driven by renewed energy security concerns. However, consensus already embeds strong growth into FY27 (Visible Alpha EBITA +12% YoY) which is well above industry forecast growth rates. With capex expectations continuing to soften in the key Energy end-market and the order book likely to roll over at the FY26 result, we retain our conservative view. We reduce our EBITA forecasts by 8-9% across our forecast period and cut our target price to $10.80 (from $11.80). HOLD maintained.
News & insights
July 17, 2026
July 16, 2026
min read
Super condition of release: when can you access your super?
Raymond Chan (AR: 000259387)
Private Client Adviser / Head of Asian Desk
July 17, 2026
July 14, 2026
min read
Is Australia an Oil Export Country?
Raymond Chan (AR: 000259387)
Private Client Adviser / Head of Asian Desk


